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Abstract
Background: In the current study we investigated the role of caveolin-1 (cav-1) in pancreatic
adenocarcinoma (PC) cell migration and invasion; initial steps in metastasis. Cav-1 is the major
structural protein in caveolae; small Ω -shaped invaginations within the plasma membrane. Caveolae
are involved in signal transduction, wherein cav-1 acts as a scaffolding protein to organize multiple
molecular complexes regulating a variety of cellular events. Recent evidence suggests a role for cav-
1 in promoting cancer cell migration, invasion and metastasis; however, the molecular mechanisms
have not been described. The small monomeric GTPases are among several molecules which
associate with cav-1. Classically, the Rho GTPases control actin cytoskeletal reorganization during
cell migration and invasion. RhoC GTPase is overexpressed in aggressive cancers that metastasize
and is the predominant GTPase in PC. Like several GTPases, RhoC contains a putative cav-1 binding
motif.
Results: Analysis of 10 PC cell lines revealed high levels of cav-1 expression in lines derived from
primary tumors and low expression in those derived from metastases. Comparison of the BxPC-3
(derived from a primary tumor) and HPAF-II (derived from a metastasis) demonstrates a reciprocal
relationship between cav-1 expression and p42/p44 Erk activation with PC cell migration, invasion,
RhoC GTPase and p38 MAPK activation. Furthermore, inhibition of RhoC or p38 activity in HPAF-
II cells leads to partial restoration of cav-1 expression.
Conclusion: Cav-1 expression inhibits RhoC GTPase activation and subsequent activation of the
p38 MAPK pathway in primary PC cells thus restricting migration and invasion. In contrast, loss of
cav-1 expression leads to RhoC-mediated migration and invasion in metastatic PC cells.
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Background
Caveolin-1 (cav-1) is the major structural component of
small Ω -shaped plasma membrane invaginations called
caveolae [1]. Caveolae regulate plasma membrane signal
transduction, with cav-1 acting as a scaffolding molecule
to sequester and organize multi-molecular signaling com-
plexes [2,3]. Many proteins which regulate multiple cellu-
lar activities such as growth and survival contain a
putative cav-1 binding domain [2-4]. Recent evidence sug-
gests a crucial role for cav-1 in regulating cellular migra-
tion and metastasis[5-7]. In a tumor progression model of
breast cancer, loss of cav-1 corresponded to increased
metastasis, while ectopic expression of cav-1 inhibited
metastasis[8]. Furthermore, disruption of the Cav-1 gene
in transgenic mice promotes mammary tumorigenesis
and increased formation of metastases[9]. Conversely, in
esophageal squamous cell carcinoma, lung adenocarci-
noma, prostate, colon and clear cell renal cancers, high
levels of cav-1 protein is associated with increased meta-
static potential[10-12]. The molecular mechanism(s) of
how cav-1 regulates tumor cell migration and metastasis
has not been thoroughly explored.
Recent immunohistochemical studies have implicated
increased cav-1 expression as a poor prognostic factor for
pancreatic adenocarcinoma (PC) [13]. In the present
study, we set out to determine whether cav-1 played a role
in PC cell migration and invasion; initial steps in the met-
astatic cascade. Additionally, we attempted to identify the
molecules regulated by cav-1 that are involved in PC cell
migration and invasion.
Numerous molecules have been identified which interact
with cav-1 [14-18]. Among these are the small monomeric
GTPases Ras and RhoA [3,4]. The Ras Homology or Rho-
subfamily of GTPases are typically involved in actin
cytoskeleton rearrangement during cellular migration
(reviewed in [19]). RhoC GTPase is a member of the Rho-
subfamily that is associated with aggressive and highly
metastatic tumors including PC [20-28].
Several studies have implicated RhoC as the predominant
Rho GTPase in PC tumors and its expression is associated
with metastasis and decreased survival (6 month versus
12 month for patients whose tumor expressed low or no
RhoC) [29]. In a study aimed at characterizing genes
involved in PC, laser capture microdissection (LCM) was
used to compare normal pancreatic ductal cells with pan-
creatic cancers by cDNA microarray analysis [30]. RhoC
was overexpressed and found in primary tumors that were
locally invasive and in tumors from a variety of metastatic
sites [30]. Another cDNA microarray study compared
LCM isolated samples from 10 PC tumor specimens with
5 chronic pancreatitis and 5 normal pancreas specimens
[31]. In PC tumors, RhoC was overexpressed 3- to 6-fold
compared to normal and 2- to 4-fold compared with
chronic pancreatitis (Craig Logsdon, personal communi-
cation) [31]. In each of these studies RhoA, Rac1 and
Cdc42 were not significantly altered nor were they associ-
ated with aggressive or metastatic disease.
Similar to Ras, Rho GTPases are activated by a complex
network of regulatory proteins and exists in the cell in an
inactive GDP-bound and active GTP-bound state [32,33].
Unlike Ras, no activating mutations have been identified
for Rho proteins in human cancers [32,33]. Therefore,
increased Rho activity appears to be due to aberrant
expression and/or dysregulation of regulatory pro-
teins[32,33]. Like several Rho-subfamily members, RhoC
contains a putative cav-1 binding domain. In the present
study we demonstrate that cav-1 expression in PC cell
lines regulates RhoC activation and cellular migration and
invasion through the mitogen activated protein kinase
(MAPK) pathway.
Results
Caveolin-1 Expression in Pancreatic Cancer Cell Lines
Ten pancreatic adenocarcinoma (PC) cell lines were
obtained from ATCC and compared with immortalized
human pancreatic ductal epithelial (HPDE) cells for cave-
olin-1 (cav-1) expression. Figure 1A are the results of
immunoblot analysis for total cellular cav-1 protein
expression. Cav-1 expression was variable among the cell
lines, with high cav-1 levels detected in the HPDE and PC
cells derived from primary tumors (BxPC-3 and MiaPaCa-
2). Comparatively, cav-1 levels in immortalized HPDE
cells were lower than the BxPC-3 and MiaPaCa-2 cell
lines. Expression was low or absent in cell lines derived
from metastatic tumors or ascites fluid (HPAF-II, Capan-
1, SW1990, SU86.86, Capan-2 and AsPc-1). The exception
to this is the CFPAC-1 cell line, which was derived from a
liver metastasis in a patient that had chronic cystic fibro-
sis. Interestingly, the Panc-1 cell line, which was derived
from an invasive intraductal extension of a primary
tumor, had an intermediate expression level. These results
suggest that high cav-1 expression may be associated with
primary tumors, while loss of cav-1 may be associated
with metastases.
To determine whether cav-1 expression plays a central role
in cell migration and invasion we chose the BxPC-3 and
HPAF-II cell lines to represent tumor cells derived from
primary tumors and metastases, respectively. Morpholog-
ically, both of the cell lines are similar and have a well-dif-
ferentiated, epithelial appearance. We first tested the cells
in a colloidal gold random motility assay to assess basal,
non-ECM mediated migratory capabilities of cells. Figure
1B shows that after 16 h the BxPC-3 cell line was essen-
tially non-migratory with an average phagokinetic track
area of 357 ± 107 square pixels in contrast to the HPAF-IIMolecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
Page 3 of 14
(page number not for citation purposes)
Caveolin-1 expression in human pancreatic adenocarcinoma cell lines Figure 1
Caveolin-1 expression in human pancreatic adenocarcinoma cell lines. Panel A is a comparison of caveolin-1 protein expression 
in human ductal pancreatic epithelial (HPDE) and 10 pancreatic cancer cell lines. Aliquots of 50 µg total protein were probed 
by immunoblotting with a monoclonal antibody specific for caveolin-1. Both the α  and β  isoforms of caveolin-1 were detected. 
Immunoblot analysis of β -actin served as a loading control. B. Comparison of BxPC-3 and HPAF-II migration in a colloidal gold 
random migration assay. PC cells were seeded onto coverslips coated with colloidal gold, stimulated by the addition of 10% 
FBS and allowed to migrate for 16 h at 37°C. Phagokinetic tracks were photographed and areas measured. Invasion was meas-
ured by a Matrigel invasion assay using 10% serum as a chemoattractant. C. HPAF-II cells were transiently transfected with 
GFP-cav-1 or GFP only and their migratory capabilities measured in a blue-fluorescent bead migration assay in a manner identi-
cal to what was described for the colloidal gold assay. A representative Western blot demonstrating that ectopic cav-1 protein 
levels in the HPAF-II cells were similar to the BxPC-3 cell line. Phagokinetic tracks from GFP-expressing cells were imaged and 
areas measured. GFP-cav-1 cells were significantly less migratory (*p = 0.0032) and less invasive (*p = 0.002) than the controls.Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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cell line which was highly migratory with an average track
area of 1567 ± 227 square pixels. Similarly, when tested
for their ability to invade through a Matrigel coated filter
in response to a serum chemoattractant, the HPAF-II cells
were 10-fold more invasive than the BxPC-3 cells.
Next we sought to establish whether loss of cav-1 was
responsible for the increased migratory and invasive capa-
bilities of the HPAF-II cells. To accomplish this we tran-
siently transfected the HPAF-II cells with a GFP-tagged
cav-1 expression vector. Using a variation of the colloidal
gold assay, we compared untransfected, GFP-vector con-
trol and GFP-cav-1 transfected HPAF-II cells in a blue flu-
orescent bead random migration assay. This assay is
performed the same as the colloidal gold assay, but allows
us to fluorescently identify GFP-transfected cells. Figure
1C demonstrates that ectopic re-expression of cav-1 to lev-
els similar to that of the BxPC-3 cells significantly
decreases HPAF-II migration (890 ± 67 square pixels; p =
0.0032) compared with the untransfected or GFP-vector
control HPAF-II cells (1630 ± 183 and 1435 ± 235 square
pixels, respectively).
Similarly in a Matrigel invasion assay, re-expression of
cav-1 in the HPAF-II cells decreased the invasiveness of the
cells nearly 2-fold compared with the controls. The results
from the motility and invasion experiments suggest that
HPAF-II migration and invasion is mediated by cav-1.
RhoC GTPase Induces PC Cell Migration
Due to their role in cellular migration, invasion and
metastasis the Rho GTPases were logical molecular candi-
dates to interact with cav-1 to mediate cell migration and
invasion. RhoC GTPase is prevalent in metastatic tumors,
particularly in PC [20-28]. Hence, we chose to study RhoC
GTPase in relationship to cav-1. As shown in Figure 2A
RhoC GTPase is expressed on the protein level to varying
degrees in the panel of 10 pancreatic cancer cell lines that
were analyzed for cav-1 expression. However, more
important than expression is the activation state of the
GTPase. Figure 2B is a comparison of RhoC expression
and activation in the BxPC-3 and HPAF-II cell lines. RT-
PCR and immunoblot analysis confirm that RhoC is
highly expressed on the mRNA and protein levels both in
the BxPC-3 and HPAF-II cells. To determine the relative
levels of active RhoC in these cell lines, a GST fusion pro-
tein of the Rho-binding domain of the downstream Rho
effector protein, rhotekin, was used to selectively pull out
GTP-bound RhoC. Although levels of total GDP/GTP-
bound RhoC were similar for both cell lines, levels of
active RhoC was considerably higher in the HPAF-II cell
line.
To determine if cav-1 expression affected RhoC activation,
levels of GTP-bound RhoC was measured in the GFP-cav-
1 and control HPAF-II cells (Figure 2C). Compared with
the controls, transient ectopic re-expression of cav-1
decreased levels of active RhoC by 6-fold without effecting
total RhoC protein levels, suggesting regulation of RhoC
activation by cav-1.
Next, to directly implicate RhoC in PC cell migration and
invasion, we generated stable HPAF-II dominant negative
RhoC (dnRhoC) transfectants. For clarity and simplicity
the results shown are from a polyclonal population which
is representative of three individual clones that were
tested. Figure 3A shows a 57% decrease of active RhoC in
the HPAF-II/dnRhoC transfectants compared with the
untransfected and vector transfected controls. As a posi-
tive control the HPAF-II cells were treated with C3
exotransferase. C3 exotransferase is a toxin derived from
Clostridium botulinum and is effective at inhibiting RhoA, -
B and -C activity with virtually no effect on Rac1 or Cdc42
[34,35]. C3 exotransferase treatment reduced active RhoC
levels by 85%. As shown, both C3 exotransferase
treatment and expression of dnRhoC did not significantly
alter total levels of RhoC protein.
Dominant negative Rho GTPases work by entering into a
non-productive interaction with Rho Guanine Exchange
Factors (RhoGEFs), the proteins which catalyze the
exchange of GDP for GTP. Due to the close homology
between RhoC and RhoA (91% on the protein level), the
possibility exists that both GTPases can be activated by the
same RhoGEFs in vivo. As shown in Figure 3B, RhoA activ-
ity was not significantly altered by expression of dnRhoC.
Again, as a positive control HPAF-II cells were treated with
C3 exotransferase; this reduced RhoA activity an average
of 63%. Therefore, RhoC activity was specifically
decreased in the HPAF-II cells expressing dominant nega-
tive RhoC.
As shown in Figure 3C, inhibition of RhoC activity, either
by dnRhoC or by treatment with C3 exotransferase, signif-
icantly reduced HPAF-II cell migration by nearly 4-fold (p
= 0.001) and invasion by 3-fold (p = 0.023), suggesting a
key role for RhoC GTPase mediating HPAF-II cell migra-
tion and invasion.
Association of Cav-1 and RhoC GTPase in PC cells
Next, we considered the possibility that RhoC activity and
PC migration and invasion are regulated by cav-1 through
physical interaction of the GTPase with the scaffolding
protein. Proteins that associate with cav-1 contain the
canonical cav-1 binding domain, Φ XΦ XXXXΦ  or
Φ XXXXΦ XXΦ  (where Φ = Trp, Phe or Tyr) [36,37]. A
review of the RhoC protein sequence revealed a putative
cav-1 binding sequence at amino acid residues 35–43
(YVPTVFENY).Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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Figure 4A are the results of immunoprecipitation assays
using either a polyclonal or monoclonal antibody specific
for cav-1 followed by immunoblotting for RhoC. Cav-1
and RhoC proteins co-immunoprecipitated in the BxPC-3
cells but not in the HPAF-II cell line. Unexpectedly, the
association between cav-1 and RhoC was restored in the
HPAF-II/dnRhoC cell line suggesting that inhibition of
RhoC activity leads to re-expression of cav-1 protein.
The results of a cav-1 immunoblot for total cellular pro-
tein are shown in Figure 4B. Expression of cav-1 was
increased 3.1-fold in the HPAF-II/dnRhoC cells compared
with the parental HPAF-II and vector control cells. Actin
was used as a loading control. Together with the immuno-
precipitation data, these data suggest that cav-1 expression
is in a reciprocal relationship with RhoC activation. High
cav-1 protein expression leads to inhibition of RhoC
RhoC GTPase expression in BxPC-3 and HPAF-II cell lines Figure 2
RhoC GTPase expression in BxPC-3 and HPAF-II cell lines. A. Total GDP/GTP-bound RhoC was measured in a panel of 10 PC 
cell lines. Protein (30 µg) was harvested from actively growing PC cell lines. B. Expression of RhoC in BXPC-3 and HPAF-II 
cells was measured by RT-PCR and immunoblot analysis using RhoC-specific primers and antibody, respectively. To determine 
the amount of active, GTP-bound RhoC a Rho activation assay was performed. GST-rhotekin is used to pull down RhoC-GTP 
from total cell lysates followed by immunoblotting with a RhoC-specific antibody. C. The RhoC activation assay was performed 
on the GFP-cav-1 HPAF-II transfectants 24 h after transfection. Differences in active and total RhoC levels were measured by 
densitometry and are represented.Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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Establishment of stable, dominant negative RhoC HPAF-II transfectants Figure 3
Establishment of stable, dominant negative RhoC HPAF-II transfectants. A. Results of a RhoC activation assay and total RhoC 
Western blot comparing wildtype, C3 exotransferase treated, vector control and dominant negative RhoC (dnRhoC) trans-
fected HPAF-II cells. B. Comparison of total (dark grey) and active (light grey) RhoA levels utilizing a RhoA-specific antibody. C. 
Results of the effect of dnRhoC transfection and C3 treatment on HPAF-II cells in a colloidal gold migration assay. Inhibition of 
RhoC lead to a significant decrease in migration (*p = 0.001) and invasion (*p = 0.023).Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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activation while inhibition of RhoC activity leads to par-
tial re-expression of cav-1. Furthermore, interaction of
cav-1 and RhoC may result in decreased RhoC activation,
limiting cell migration and invasion.
PC Cell Migration Involves the Mitogen Activated Protein 
Kinase (MAPK) Pathway
Previous studies demonstrated that activation of p42/p44
extracellular regulated kinase (Erk) decreased cav-1
Interaction of cav-1 and RhoC in BxPC-3 and HPAF-II PC cell lines Figure 4
Interaction of cav-1 and RhoC in BxPC-3 and HPAF-II PC cell lines. A. Aliquots of 500 µg total protein from BxPC-3, HPAF-II 
and HPAF-II/dnRhoC transfectants were immunoprecipitated with either a monoclonal or polyclonal antibody to cav-1. Pro-
teins were separated by SDS-PAGE, transferred to nitrocellulose and probed with either a RhoC-specific or cav-1 antibody. 
Normal IgG negative controls are also shown. B. Immunoblot analysis of 50 µg of total protein for total cav-1 expression using 
a cav-1 specific monoclonal antibody and actin was measured as a loading control. Densitometry was performed on each blot 
and expression levels were normalized to the actin control. Expression levels are represented as arbitrary units (AU).Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
Page 8 of 14
(page number not for citation purposes)
protein levels in constitutively-active Ras transformed
NIH3T3 cells [38]. In the same set of studies it was shown
that inhibition of oncogenic Ras-induced Erk activation
with PD98059 increased cav-1 expression 5-fold [38].
That same group also demonstrated that ectopic re-expres-
sion of cav-1 decreased Erk activation in Ras-transformed
CHO cells [39]. Our laboratory has previously
demonstrated that RhoC can mediate inflammatory
Analysis of the mitogen activated protein kinase pathway (MAPK) in the BxPC-3 and HPAF-II cells Figure 5
Analysis of the mitogen activated protein kinase pathway (MAPK) in the BxPC-3 and HPAF-II cells. A. Actively growing PC cells 
were serum starved for 24 h and left untreated or pretreated for 1 h with 5 µg C3 exotransferase, stimulated by the addition 
of 10% serum and proteins harvested 15 min later. Activated p42/p44 Erk and p38 MAPK were detected by antibodies specific 
for the phosphorylated forms of each of those proteins. Immunoblots were stripped and reprobed with antibodies specific for 
total forms of each protein. B. Comparison of active p42/p44 Erk and p38 MAPK in GFP-cav-1 and GFP-vector transient trans-
fectants at 24 h after transfection. C. Results of a colloidal gold migration assay after 30 min pre-treatment of cells with 30 µM 
of either PD98059 or SB220025. Phagokinetic tracks were imaged at 6 h after stimulation. Results are given for DMSO control 
(dark grey), PD98059 treated (medium grey) and SB220025 treated (light grey). SB220025 treatment of the HPAF-II cells led to 
a significant decrease (*p = 0.001) in migration and invasion. Levels of cav-1 protein were increased, while active RhoC was 
decreased in SB220025 treated HPAF-II cells.Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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breast cancer cell migration and invasion through co-acti-
vation of the p42/p44 Erk and p38 arms of the MAPK
pathway [40]. With these studies in mind we next exam-
ined whether RhoC can activate p42/p44 Erk in PC, sub-
sequently decreasing cav-1 expression and leading to
increased cellular migration. Also, we examined the
potential involvement of p38 MAPK in this process.
Figure 5A is a comparison of active (phospho-) and total
levels of p42/p44 Erk and p38 MAPK in BxPC-3, HPAF-II
and HPAF-II/dnRhoC cells that were serum starved for 16
h and stimulated with 10% serum alone or after pre-treat-
ment with C3 exotransferase. Although active phospho-
Erk levels were stimulated in both cell lines, active p42/
p44 Erk was considerably higher in the BxPC-3 cell line
compared with the HPAF-II cell line. Pretreatment with
C3 exotransferase slightly decreased active Erk in serum
stimulated cell lines. Similar results were previously dem-
onstrated and are unexpected since the HPAF-II cell line
harbors an activating G12D K-Ras mutation, while the
BxPC-3 cell line has a wildtype K-Ras [41,42]. In the
HPAF-II/dnRhoC cells, the overall phospho-p42/p44 lev-
els were higher compared with the parental HPAF-II cell
line suggesting that inhibition of RhoC leads to increased
Erk activation.
Converse to what was observed for p42/p44 Erk the levels
of phospho-p38 MAPK were low in the BxPC-3 and
HPAF-II/dnRhoC cells and higher in the HPAF-II cells. C3
treatment decreased p38 activity in the BxPC-3 and HPAF-
II cell lines. The levels of active p38 in the HPAF-II/
dnRhoC and C3 treated HPAF-II cells were comparable;
demonstrating an approximate 52% decrease in activity
compared with the serum stimulated HPAF-II cells. Taken
together, an inverse relationship between p42/p44 Erk
and p38 MAPK signaling is suggested in the PC cells.
Levels of active Erk and p38 MAPK were assessed in the
HPAF-II/GFP-cav-1 transfectants. As shown in Figure 5B,
levels of active phospho-p42/p44 Erk increased in the
GFP-cav-1 transfectants compared with the untransfected
and control GFP-vector transfectants. Conversely, levels of
phosphorylated p38 decreased in the cav-1 transfectants,
mirroring what is observed in the HPAF-II/dnRhoC cells.
To tease out the individual roles of the p42/p44 Erk and
p38 MAPK pathways in PC cellular migration, the BxPC-3
and HPAF-II cells were treated with the pharmacologic
inhibitors PD98059 (to inhibit MEK1 and subsequently
Erk) or SB220025 (to inhibit p38) and tested in migration
and invasion assays (Figure 5C). SB220025 treatment sig-
nificantly reduced HPAF-II migration and invasion (p =
0.001). PD98059 treatment had no effect on the cells abil-
ity to move in either assay suggesting that migration and
invasion occurs through signaling of the p38 MAPK
pathway.
Changes in cav-1 expression due to inhibitor treatment
are also shown in Figure 5C. Cav-1 expression was slightly
less after PD98059 treatment in both PC cell lines.
Treatment with SB220025 increased cav-1 expression dra-
matically in the HPAF-II and slightly in the BxPC-3 cells,
implying a reciprocal relationship between cav-1
expression and p38 activation. Furthermore, RhoC activ-
ity was appreciably reduced in the SB220025 treated
HPAF-II cells strengthening the notion that cav-1 is in a
reciprocal relationship with RhoC and p38 activity.
Methyl-β -cyclodextrin increases PC cell motility
Lastly, we treated the BxPC-3 cell line with methyl-β -
cyclodextrin (Mβ CD), which sequesters cholesterol, dis-
rupts caveolae and mis-localizes cav-1 in the cell [43]. As
shown in Figure 6A, Mβ CD treatment significantly
increased the area of BxPC-3 migration (p = 0.0001).
Increased cellular migration was accompanied by a signif-
icant increase in active GTP-bound RhoC (Figure 6B; p =
0.0001). Consistent with previous observations, Figure
6C demonstrates that levels of phospho-p42/p44 Erk in
the Mβ CD treated cells decreased while levels of phospho-
p38 MAPK increased. The changes in MAPK proteins
approached but did not achieve statistical significance.
These data further suggest that activation of RhoC GTPase
is regulated by cav-1 and that RhoC signals through the
p38 arm of the MAPK pathway to induce cellular
migration.
Discussion
Both loss and overexpression cav-1 has been described in
tumor progression, sometimes within the same tumor
type [44-47]. Loss and overexpression of cav-1 has also
been associated with the progression to a metastatic phe-
notype within different cancers [47,8]. However, the
molecular mechanism(s) by which cav-1 confers meta-
static ability has not been thoroughly explored. Here we
present evidence for the involvement of RhoC GTPase and
p38 MAPK in the migratory and invasive phenotype after
loss of cav-1 expression in PC cells.
Immunohistochemical staining of primary human PC
tumors demonstrated that high cav-1 expression corre-
lated with large PC tumor size and a poor prognosis [13].
In our current study we found that PC cell lines derived
from primary tumors have high cav-1 expression while
those derived from distant metastases have significantly
reduced or lost expression. Two recent studies have dem-
onstrated a biphasic expression of cav-1 in primary vs.
metastatic tumors [48,49]. Both in renal cell and oral car-
cinomas, cav-1 is overexpressed in primary tumors but
low or absent in distant metastases. It is possible thatMolecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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biphasic expression of cav-1; meaning, overexpression in
primary tumors and low or absent expression in metas-
tases occurs in pancreatic cancer.
Many proteins including the majority of the Rho GTPases
have the ability to associate with cav-1 [3,4,14-18]. RhoC
has been shown to be the predominant Rho protein in PC
and is associated with particularly aggressive disease [21-
29]. Given the role of RhoC in cellular migration and its
prevalence in metastatic tumors, it was a logical choice to
examine in relationship to cav-1.
One effect that high cav-1 expression could have in PC
cells is regulating RhoC activity, thus limiting cell migra-
tion and promoting growth. This could potentially
explain why PC cells harboring activating K-Ras muta-
tions have lower activated phospho-p42/p44 Erk levels
than expected [41,42]. Our data suggest that expression of
Effect of disruption of caveolae and mis-localization of caveolin-1 after treatment of BxPC-3 cells with Mβ CD Figure 6
Effect of disruption of caveolae and mis-localization of caveolin-1 after treatment of BxPC-3 cells with Mβ CD. A. Results of a 
colloidal gold random motility assay performed after a 1 h pre-treatment of BxPC-3 cells with 5 mM Mβ CD in growth medium. 
Phagokinetic tracks were measured 16 h after stimulation. Mβ CD treated BxPC-3 cells were significantly more migratory than 
untreated cells (* p = 0.0001) B. Total (light grey) and active GTP-bound (dark grey) levels of RhoC were measured in Mβ CD 
treated BxPC-3 cells 3 h after treatment. A statistical difference in RhoC activation was reached with a p value of 0.0001. C. 
Immunoblot analysis of basal levels of active (light grey) and total (dark grey) p42/p44 Erk and p38 MAPK in Mβ CD treated 
BxPC-3 cells 3 h after treatment.Molecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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high cav-1 levels in primary PC tumor cells favor the p42/
p44 Erk pathway which is associated with cell growth and
survival (reviewed in [50]). When cav-1 expression is
diminished or lost, the p38 MAPK pathway is favored and
cell migration occurs. Data in the current study also indi-
cate that the p38 MAPK pathway leads to RhoC-mediated
PC cell migration and invasion, while the Erk pathway
does not. This is contrary to what we had demonstrated
for RhoC-mediated migration and invasion in inflamma-
tory breast cancer [40].
Experiments in NIH3T3 and CHO cells suggest a recipro-
cal and reversible relationship between p42/p44 Erk acti-
vation and cav-1 expression [38,39]. Our data suggests
that this is not the case in PC cells. High cav-1 expression
is associated with higher levels of active p42/p44 irregard-
less of K-Ras mutational status. The same studies also sug-
gested a role for active protein kinase A (PKA) in reversibly
suppressing cav-1 expression [38,39]. Our early studies
suggested that this is also not the case in PC cells (data not
shown). Instead our data suggest that suppression of
RhoC or p38 MAPK activity restores cav-1 expression and
suppresses migration and invasion.
This study is the first to draw a functional link between
RhoC and cav-1 and to demonstrate involvement of the
MAPK signal transduction pathway. This study also
presents a fresh link to the regulation of RhoC-mediated
migration and invasion, giving a functional role for RhoC
in PC tumor cells.
Conclusion
This study suggests that cav-1 expression suppresses RhoC
GTPase activation and RhoC-mediated cellular migration
and invasion. Further, expression of cav-1 favors activa-
tion of the p42/p44 Erk pathway, perhaps promoting
growth and survival. Loss of cav-1 expression leads to
increased RhoC activation favoring the p38 MAPK path-
way and cellular migration and invasion. Inhibition of
RhoC or p38 activation results in decreased cellular move-
ment and partial re-expression cav-1 protein. These results
may imply a biphasic expression of cav-1 during PC
tumor progression promoting growth and survival in the
primary tumor cells and motility in the metastatic cells.
Lastly, this study suggests a functional role for RhoC
GTPase in PC migration and invasion.
Methods
Cell Culture
All pancreatic cancer (PC) cell lines were obtained from
American Type Culture Collection (ATCC; Rockville, MD)
and grown in their required growth medium per ATCC
description. Specifically, BxPC-3 cells were grown in 90%
RPMI 1640 (Bio Whittaker, Walkersville, MD), 10% FBS
(Biosource International, Rockville, MD) and HPAF-II
cells in 90% EMEM (Bio Whittaker), 10% FBS. Human
pancreatic ductal epithelial (HPDE) cells (a gift from Dr.
Ming Sound Tsao) were grown in keratinocyte serum-free
(KSF) medium with 0.2 ng/ml EGF and 30 µg/ml bovine
pituitary extract (InVitrogen Gibco, Carlsbad, CA)
[51,52]. In the inhibitor studies, cells were pre-incubated
for 0.5 h with 30 µM PD98059 or SB220025, (Calbio-
chem, San Diego, CA) or as a control, with DMSO carrier
and stimulated with normal growth medium. C3
exotransferase (5 µg) was introduced into cells as previ-
ously described using a lipid transfer mediated method
[53,40] and treated for 1 h before analysis. BxPC-3 cells
were treated with 5 mM Mβ CD in medium for 2 h.
Plasmids and Transfection
Wild type human cav-1 was cloned from immortalized
HPDE cells by RT-PCR. Total RNA was isolated from
HPDE cells by Trizol (InVitrogen) and cDNA synthesized
with the Wizard AMV-reverse transcriptase kit (Promega,
Madison, WI). A 10 µl aliquot of cDNA was amplified by
PCR, ligated into the pGEM-T Easy vector (Promega), and
sequenced by the University of Michigan DNA sequencing
core. The cav-1 sequence was confirmed using the NCBI
BLAST database. The internal stop codon was removed
using QuikChange (Stratagene, La Jolla, CA) and the
insert transferred to pcDNA3.1/CT-GFP (InVitrogen).
Cav-1 constructs were transiently transfected into PC cells
using FuGene6 (Roche, Indianapolis, IN) and assayed 24
h later. Empty vector was used as a transfection controls.
Dominant negative RhoC (dnRhoC) in pcDNA3.1 was
obtained from Guthrie cDNA resource center. The
dnRhoC construct or vector control was introduced into
HPAF-II cells using FuGene6 and stable transfectants
established by growing cells continuously in 250 µg/ml
neomycin. Individual clones as well as a polyclonal pop-
ulation were chosen and tested in these experiments.
Expression of the transgene was confirmed by RT-PCR for
sequences unique to the plasmid. The results of the poly-
clonal population are reported because they are represent-
ative of the data obtained from all the clones.
RT-PCR Analysis
RT-PCR of RhoC expression in PC cell lines was per-
formed as previously described [54] using primers specific
for RhoC GTPase and GAPDH control. Triplicate analysis
of RT-PCR was performed.
Immunoprecipitation/Western Blot Analysis
Protein was harvested from cells using RIPA buffer as pre-
viously described [54]. Lysates were separated by SDS-
PAGE on a 4–15% gel, transferred to nitrocellulose,
blocked and probed with a polyclonal antibody for RhoC
[55], monoclonal antibodies for cav-1, (Pharmingen, San
Diego, CA), RhoA (Cytoskelton Inc., Denver, CO.) or total
and phospho- p42/p44 MAPK and p38 MAPK (CellMolecular Cancer 2005, 4:21 http://www.molecular-cancer.com/content/4/1/21
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Signaling Technologies, Beverly, MA). After incubation
with a goat anti-rabbit-HRP or goat anti-mouse-HRP anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), immu-
noblots were developed with Lumiglo (Cell Signaling
Technologies), exposed to Hyperfilm (Amersham, Piscat-
away, NJ) and images recorded on an Alpha Image 950
documentation system (Alpha Innotech, San Leandro,
CA). Densitometry was performed using ImageJ software
(version 1.30; available from the NIH at http://
rsb.info.nih.gov/ij/). Immunoprecipitation experiments
were preformed by pre-incubating 1 mg of protein lysate
with normal isotype control for 1 h followed by an over-
night incubation with a polyclonal or monoclonal anti-
body for cav-1 (Pharmingen) and Protein A/G agarose
PLUS (Santa Cruz) at 4°C. Precipitates were repeatedly
pelleted by brief centrifugation followed by 4 washings
with ice-cold PBS. Proteins were separated by SDS-PAGE
on a 15% gel, transferred to nitrocellulose, blocked and
probed with a polyclonal antibody to RhoC and exposed
as described above.
Rho Activation Assay
Rho activation assay reagents were supplied to us by John
Collard, Ph.D. at the Netherlands Cancer Institute [56,57]
and used to determine activation of RhoC in PC cells.
Cells, 5–10 × 106 cells/assay, were grown in fresh serum-
containing medium for 16 h and lysed with ice-cold GST-
FISH buffer (10% Glycerol, 50 mM Tris pH 7.4, 100 mM
NaCl, 1% NP-40 and 2 mM MgCl2). Protein lysates, 900
µl of 1 µg/µl, were precleared with glutathione sepharose
for 1 h at room temperature. The cleared lysates were
incubated with GST-rhotekin-sepharose conjugate at 4°C
for 30 min. The sepharose conjugate was collected by cen-
trifugation, resuspended in Laemelli buffer, separated by
SDS-PAGE, transferred to nitrocellulose and probed with
a RhoC antibody developed by our laboratory [55]. Den-
sitometry was performed as described above. The results
of triplicate assays were combined and described as per-
cent of Rho activation detected in the wild-type cell line.
Random Migration and Invasion Assays
Colloidal gold random migration assays were performed
as previously described [54]. Random migration assays
were also performed using the blue fluorescent bead
motility HitKit (Cellomics, Pittsburg, PA). Cells, 200/well
in serum free medium (SFM), were seeded onto a lawn of
blue fluorescent beads in a BSA coated 96-well plate (BD
Biosciences, San Diego, CA). Cells were stimulated 1 h
later with 10% FBS, incubated 6 h at 37°C, and fixed.
Cells were visualized by fluorescent microscopy, digitally
recorded and the areas of phagokinetic tracks measured
using the ImageJ software. Migration assays were per-
formed at least three separate times and at least 250 cell
tracks were measured per condition in each analysis.
The Matrigel invasion assays were performed as previ-
ously described using pre-coated Transwell filters with 8 µ
pores [58,54]. Cells were harvested and resuspended in
serum-free medium containing 0.1% BSA at a
concentration of 3.75 × 105 cells/ml, and 0.5 ml was
added to the top chambers and placed for 24 h at 37°C in
a 10% CO2 incubator. The cell suspension was aspirated
from the top chamber of all three assays. Excess Matrigel
was removed from the invasion assay filter using a cotton
swab. The filters were then cut away from the Transwell
assembly, fixed top side down with methanol to a glass
microscope slide, stained with H&E, and the entire surface
of the filters counted. The number of cells that moved in
serum-free (i.e. no chemoattractant) controls was
considered background and was subtracted from the
number of cells counted in the samples containing
chemoattractant.
Statistical Analysis
All experiments and assays were performed a minimum of
three separate times. Statistical analysis was performed by
the University of Michigan Biostatistics Core using the
Wilcoxon rank-sum analysis and Students t-test.
Abbreviations
PC, pancreatic cancer; cav-1, caveolin-1; MAPK, mitogen
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